Barrett's Esophagus Clinical Trial
— HALOOfficial title:
Single Center Patient Registry Using Radio Frequency Ablation of Barrett's Esophagus Using HALO System
The purpose of this study is to provide a tool for physicians to compare outcome data related to the use of the HALO Ablation Systems. This study is a single-center patient registry which will contribute to a framework for treatment and follow-up of patients with Barrett's Esophagus.
Status | Not yet recruiting |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | November 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - candidate for ablation of Barrett's Esophagus with the HALO Ablation System (Prospective) - received an ablation with the HALO Ablation System to treat Barrett's Esophagus (Retrospective) - candidate agrees to proposed follow-up schedule of yearly surveillance following treatment - signs consent Exclusion Criteria: - has not been diagnosed with Barrett's Esophagus |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Ochsner Medical Center | Kenner | Louisiana |
Lead Sponsor | Collaborator |
---|---|
Ochsner Health System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Histological clearance rate for dysplasia | Biopsy taken at 12 months to determine effectiveness | No | |
Primary | Endoscopic clearance rate for Barrett's Esophagus | Outcome measure is assessed at Month 12 | No | |
Secondary | Histological clearance rate for intestinal metaplasia | Biopsy taken at 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02864043 -
Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System
|
N/A | |
Recruiting |
NCT02018367 -
Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma
|
Phase 2 | |
Terminated |
NCT01572987 -
Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus
|
N/A | |
Terminated |
NCT01976351 -
Imaging Enhanced Endoscopy for the Screening of Barrett's Esophagus
|
N/A | |
Terminated |
NCT00526786 -
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
|
Phase 4 | |
Completed |
NCT01401699 -
Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction
|
N/A | |
Completed |
NCT02106910 -
Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy
|
N/A | |
Suspended |
NCT01580631 -
Narrow Band Imaging Project on Barrett's Esophagus
|
||
Completed |
NCT01439633 -
Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus
|
N/A | |
Completed |
NCT02879721 -
Expression and Function of the Renin-Angiotensin System in the Esophagus
|
Phase 0 | |
Completed |
NCT01439594 -
Optical Frequency Domain Imaging (OFDI) Assessment in Radiofrequency Ablation
|
N/A | |
Completed |
NCT01281618 -
Influence of Acid Reflux on Stromal Epithelial Interaction in Barrett's Esophagus
|
N/A | |
Completed |
NCT00586872 -
Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus
|
||
Completed |
NCT00844077 -
Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus
|
N/A | |
Completed |
NCT00588575 -
Ramanspectroscopy in Barrett's Esophagus
|
||
Recruiting |
NCT00288119 -
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
|
||
Completed |
NCT03813381 -
CAlorie and Protein REstriction PROgram in Barrett's Esophagus Patients (CARE-PRO).
|
N/A | |
Completed |
NCT02579460 -
Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition
|
N/A | |
Completed |
NCT01961778 -
Comparison of Treatments for Barrett's Esophagus With High-Grade Dysplasia/Early Adenocarcinoma
|
N/A | |
Completed |
NCT01733147 -
Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids
|
Phase 4 |